Abbvie was downgraded at BMO Capital to market perform from outperform. Valuation call, based on a $42 price target, BMO Capital said.
BBX was upgraded to hold at TheStreet Ratings.
Coca-Cola Enterprises was downgraded at Goldman Sachs to neutral from buy. Valuation call, based on a $40 price target, Goldman said.
CEC Entertainment was downgraded to hold at TheStreet Ratings.
Clean Harbors was upgraded at Oppenheimer to outperform from perform. $72 price target. Company is seeing higher end-market demand and has better potential for revenue synergy, Oppenheimer said.
eBay was upgraded at Canaccord Genuity to buy from hold. $67 price target. Marketplaces and PayPal can continue to drive growth, Canaccord said. $67 price target.
General Mills was downgraded at Morgan Stanley to equal-weight from overweight. $49 price target. Company lacks near-term catalysts, Morgan Stanley said.
Intel was downgraded at JMP Securities to market perform from outperform. Company will no longer pursue the Haswell architecture, JMP Securities said.
News Corp. was upgraded at Credit Suisse to outperform from neutral. $36 price target. Company should see higher cable growth and margin expansion, Credit Suisse said.
RF Micro was upgraded at Canaccord Genuity to buy from hold. $7 price target. Company can gain share in the LTE smartphone market, Canaccord Genuity said.
Regal Entertainment was downgraded at MKM Partners to neutral from buy. Company lacks near-term catalysts, MKM said.
Valassis was downgraded at Lazard Capital Markets to neutral from buy. Valuation call, based on a $36 price target, Lazard Capital Markets said.
Yahoo! was downgraded at Pivotal Research Group to hold from buy. Valuation call, based on a $26 price target, Pivotal Research said.
STOCK COMMENTS/EPS CHANGES
Alexion Pharmaceuticals numbers were cut at UBS. Shares are now seen reaching $120. Estimates were also lowerd on FDA warning letter and EU updates, UBS said. Buy rating.
BlackBerry estimates were raised at UBS through 2015. Quarter comforted by margin, lean channel, enterprise prospects, and guidance, UBS said. Neutral rating and $13 price target.
Biogen Idec numbers were raised at UBS. Shares are now seen reaching $200. Estimates were also raised on lower risk, BG-12 pricing, UBS said. Neutral rating.
Cliffs Natural Resources was added to the Analyst Focus List at J.P. Morgan. $40 price target. Capacity fears have been overblown, J.P. Morgans said.
Dell estimates were lowered at UBS through 2015. Preliminary proxy offers go private rationale, UBS said. Neutral rating and $13.65 price target.
eBay estimates, price target were raised at J.P. Morgan. Shares are now seen reaching $64. Estimates were also increased, following the company's upbeat investor meeting, J.P. Morgan said. Overweight rating.
Honeywell estimates, price target were increased at Drexel Hamilton. Estimates were raised through 2015. Company has better sales and margin visibility, Drexel Hamilton said. Buy rating and new $85 price target.
Johnson & Johnson price target was raised at UBS to $89. FDA approves Invokana, UBS said. Buy rating.
Progressive price target was raised at UBS to $25. Claims trend comparisons get easier beginning in the second quarter of 2013. Neutral rating.
Suncoke Energy was cut from the Conviction Buy List at Goldman Sachs. $19 price target. Company lacks near-term catalysts, Goldman Sachs said.
>To submit a news tip, email: firstname.lastname@example.org.